Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2000
10/18/2000CN1057525C Process improvement in synthesis of N-[3-(3-cyanopyrazolo [1,5-alpha] pyrimidin-7-yl] phenyli-N-ethyl-acetamide
10/17/2000US6133479 Phenylethylamine derivatives, processes for preparing them and their use as pharmaceutical compositions
10/17/2000US6133446 Heterocyclic compounds for the treatment of CNS and cardiovascular disorders
10/17/2000US6133442 For the treatment of disorders which are associated with endothelin activities, especially circulatory disorders such as hypertension, ischaemia, vasospasms and angina pectoris
10/17/2000US6133319 For treating an interleukin-8 (il-8) mediated disease by administering a phenyl urea or phenyl thiourea of given formula, such as n-cyclohexyl-n'-(2-hydroxy-4-nitrophenyl)urea
10/17/2000US6133302 Kynurenine-3-hydroxylase enzyme inhibitory activity, an enzyme of the kynurenine (kyn) pathway; compounds such as 5-(3-(3-fluorophenyl)-3-oxo-propyl)-1h-tetrazole; for treatment of neuropathological processes
10/17/2000US6133291 3-(piperidin-1-ylalkylene)imidazole derivatives; glaucoma, antiallergens; antiinflammation and hypotensive agents, sleeping disorders; hypermotility of the gastrointestinal tract, alzheimer's disease, schizophrenia and
10/17/2000US6133282 Agonists or antagonists at human corticotropin-releasing factor 1 (crf1) receptors; useful in diagnosis and treatment of treating stress related disorders, e.g., post trumatic stress disorder and headache; antidepressants; anxiolytic
10/17/2000US6133272 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
10/17/2000US6133268 1,4-disubstituted piperazines
10/17/2000US6133267 Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications
10/17/2000US6133257 Fused polycyclic 2-aminopyrimidine derivatives
10/17/2000US6133255 Useful in the therapy of deleterious mental states; psychological disorders
10/17/2000US6133006 Nucleotide sequence coding an enzmatic polypeptide associated with signal transduction; for the diagnosis and treatment of osteoporosis, inflammation, skin disorders, asthma, nervous system disorders, cancer, eating disorders and infections
10/17/2000US6132728 Hedgehog-derived polypeptides
10/17/2000US6131226 1,4-dihydropyridine compounds as bradykinin antagonists
10/17/2000CA2305893A1 Use of maduraphthalazine derivatives as inhibitors of proinflammatory cytokines
10/17/2000CA2178752C N-terminally chemically modified protein compositions and methods
10/17/2000CA2022484C 1-(pyridinylamino)-2-pyrrolidinones, a process for their preparation and their use as medicaments
10/15/2000CA2305940A1 Aminotriazol compounds, the process for preparing them and the pharmaceutical compositions containing them
10/12/2000WO2000060082A2 Vesicle associated proteins
10/12/2000WO2000060051A2 Arpe-19 as a platform cell line for encapsulated cell-based delivery
10/12/2000WO2000059946A1 Hydroxymatairesinol in cancer prevention
10/12/2000WO2000059941A1 Purposeful movement of human migratory cells away from an agent source
10/12/2000WO2000059939A1 COMPOUNDS AND METHODS FOR STIMULATING β-CATENIN MEDIATED GENE EXPRESSION AND DIFFERENTIATION
10/12/2000WO2000059913A1 Novel thiazolobenzimidazole derivatives
10/12/2000WO2000059909A1 Heterocyclic compounds having affinities for serotonin receptors
10/12/2000WO2000059908A2 Pyrazolopyrimidines as crf antagonists
10/12/2000WO2000059907A2 Pyrazolotriazines as crf antagonists
10/12/2000WO2000059905A1 ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS
10/12/2000WO2000059904A2 Compounds and methods to treat cardiac failure and other disorders
10/12/2000WO2000059899A1 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
10/12/2000WO2000059893A1 Neurotrophic thio substituted pyrimidines
10/12/2000WO2000059889A1 α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES
10/12/2000WO2000059888A1 N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators
10/12/2000WO2000059886A2 Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors
10/12/2000WO2000059875A2 Novel inhibitors of formation of advanced glycation endproducts (age's)
10/12/2000WO2000059874A1 NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
10/12/2000WO2000059873A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
10/12/2000WO2000059855A1 Ether compounds, compositions, and uses thereof
10/12/2000WO2000059851A1 Derivatives of venlafaxine and methods of preparing and using the same
10/12/2000WO2000059544A1 Stabilized compositions containing nootropic drugs
10/12/2000WO2000059543A1 Over-coated chewing gum formulations
10/12/2000WO2000059539A1 Method and means for treating post-polio syndrome
10/12/2000WO2000059536A1 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases
10/12/2000WO2000059511A1 Use of tianeptin in the production of medicaments to treat neurodegenerative pathologies
10/12/2000WO2000059509A1 Phthalazine derivatives for treating inflammatory diseases
10/12/2000WO2000059504A1 Method for the treatment of neurological or neuropsychiatric disorders
10/12/2000WO2000059496A1 Use of low affinity nmda antagonists for the treatment of headache
10/12/2000WO2000059495A1 (e)-styryl sulfone anticancer agents
10/12/2000WO2000059489A2 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
10/12/2000WO2000059487A2 Flupirtine in the treatment of fibromyalgia and related conditions
10/12/2000WO2000059483A2 Transdermal drug delivery devices comprising a polyurethane drug reservoir
10/12/2000WO2000059481A1 PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
10/12/2000WO2000059479A1 Pharmaceutical dosage form for pulsatile delivery of methylphenidate
10/12/2000WO2000059449A2 Purine derivatives having phosphodiesterase iv inhibition activity
10/12/2000WO2000059448A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
10/12/2000WO2000033880A3 Conjugate used for enriching in neuronal cells
10/12/2000WO1999064039A9 Bradykinin antagonists
10/12/2000WO1999041376A8 Retinoblastoma protein complexes and retinoblastoma interacting proteins
10/12/2000WO1999038841A8 Adamantanecarboximidamide derivatives and their use as nmda antagonists
10/12/2000WO1997036919A3 Cytokine designated lerk-8
10/12/2000WO1993012754A3 Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
10/12/2000CA2369945A1 Neurotrophic thio substituted pyrimidines
10/12/2000CA2369871A1 .alpha.-substituted carboxylic acid derivatives
10/12/2000CA2369557A1 Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of gabaa receptors
10/12/2000CA2369553A1 N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators
10/12/2000CA2369544A1 Aryl and heteroaryl fused aminoalkyl-imidazole derivatives:selective modulators of bradykinin b2 receptors
10/12/2000CA2369071A1 Novel lipoic acid derivatives, their preparation, pharmaceutical use and pharmaceutical compositions cantaining them
10/12/2000CA2368367A1 Pharmaceutical dosage form for pulsatile delivery of methylphenidate
10/12/2000CA2368240A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
10/12/2000CA2368083A1 Derivatives of venlafaxine and methods of preparing and using the same
10/12/2000CA2367143A1 Purine derivatives having phosphodiesterase iv inhibition activity
10/12/2000CA2367100A1 Transdermal drug delivery devices comprising a polyurethane drug reservoir
10/12/2000CA2366850A1 Method for the treatment of neurological or neuropsychiatric disorders
10/12/2000CA2366791A1 Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second cns stimulant
10/12/2000CA2366264A1 Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase
10/12/2000CA2365825A1 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases
10/12/2000CA2365500A1 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
10/12/2000CA2365421A1 Vesicle associated proteins
10/12/2000CA2365419A1 Novel thiazolobenzoimidazole derivatives
10/12/2000CA2363942A1 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
10/12/2000CA2361988A1 Use of tianeptin in the production of medicaments to treat neurodegenerative pathologies
10/11/2000EP1043308A1 Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
10/11/2000EP1043307A2 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use
10/11/2000EP1043306A2 3-amino-3-arylpropan-1-ol-derivates, their preparation and use
10/11/2000EP1043027A1 Treatment of multiple sclerosis with a combination of Interferon and Growth hormone
10/11/2000EP1043023A1 Viscous compositions containing carbon dioxide
10/11/2000EP1042674A1 148 human secreted proteins
10/11/2000EP1042498A1 A method of finding agonist and antagonist to human 11cb splice variant
10/11/2000EP1042476A1 Insulin-like growth factor binding protein fragments and the utilization thereof
10/11/2000EP1042468A2 Low-voltage activated calcium channel compositions and methods
10/11/2000EP1042460A1 Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof
10/11/2000EP1042359A1 Kappa receptor opioid peptides
10/11/2000EP1042349A1 Using polyamide nucleic acid oligomers to engender a biological response
10/11/2000EP1042318A1 Process for the preparation of paroxetine hydrochloride
10/11/2000EP1042316A1 Indole derivatives useful a.o. for the treatment of osteoporosis
10/11/2000EP1042313A1 Benzopyran and benzothiopyran derivatives having retinoid antagonist like activity
10/11/2000EP1042310A2 Method for the preparation of citalopram
10/11/2000EP1042307A1 Aminothiazole inhibitors of cyclin dependent kinases
1 ... 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 ... 1833